Introduction

Multiple sclerosis (MS) is a common, heterogenous disorder of the central nervous system (CNS) with a complex trait composed of both genetic and environmental factors. It is an inflammatory, immune-mediated chronic disorder of the CNS characterized by a combination of demyelination, axonal damage followed by degeneration and reactive gliosis (4, 7). In general, MS begins at third or fourth decade of life and affects more women than men (19). Susceptibility to MS varies in different ethnic groups (26). Although the complex pathogenesis of MS is not understood, an immune reaction against myelin sheath is suggested to be the principal event (10, 1). MS lesions are characterized by inflammatory demyelination and reactive gliosis and although remyelination occurs in some lesions, it is limited and incomplete (22). Growth factor expression could participate in the repair process of MS by modulating the activity of microglial/macrophages, and by inducing the expression of other factors that can affect myelin degeneration, and also by directly stimulating the localized proliferation and/or regeneration of oligodendrocytes within lesions area (6). Among cytokines and growth factors, brain derived neurotrophic factor (BDNF) has been shown to play a key role in neuronal and axonal survival. In the CNS, neurons are the main source of BDNF (11). Another potential source are activated astrocytes, which are present in inflamed areas in the CNS as shown in MS. In this study, total protein concentration (TPC) and BDNF levels in the cerebrospinal fluid (CSF) samples from the patients with MS (n = 48) and control subjects (n = 53) were measured using a Bio-Rad protein assay and enzyme linked immunosorbent assay (ELISA). No significant change in the CSF TPC of patients with MS was seen as compared to normal CSF. The presence of BDNF in the CSF samples was shown by Western blot. Using ELISA, it was shown that the level of BDNF in the MS CSF is higher than in normal CSF. It is concluded that BDNF is a constant component of human CSF. Moreover, it could be implicated in the pathophysiology of MS.

Key words: Brain derived neurotrophic factor; Cerebrospinal fluid; Multiple sclerosis
the brain, and changes in the cytokines and growth factor levels in the CSF have been seen in many neurological diseases (18), biochemical brain modifications could be reflected in CSF and measurements of growth factors might identify biomarkers of MS. In this study the CSF total protein concentration and BDNF levels of patients with MS was studied by Bio-Rad protein assay, western blotting and enzyme linked immunosorbsent assay (ELISA).

Materials and methods

Antibodies and reagents

Avidin-Biotin peroxidase complex and Diaminobenzidine were purchased from Vector Laboratories, Peterbrough, UK. The anti-BDNF antibody (Code: ab6201) and BDNF human ELISA (Code: ab99978) were purchased from Abcam, Cambridge, UK.

CSF samples

Forty eight patients with relapsing-remitting multiple sclerosis (RRMS) (12 males and 36 females, age ± SEM (standard error of the mean): 35.44 ± 4.33) and fifty three normal subjects (20 males and 33 females, mean age ± SEM: 37.55 ± 5.77) were recruited in this study. All patients underwent a standard battery of examinations, including medical history, physical and neurological examinations, screening laboratory test, brain magnetic resonance imaging (MRI) and lumbar puncture. All patients with RRMS were in an acute phase of the disease.

All of normal subjects underwent lumbar puncture for subjective symptoms with no evidence of objective pathological conditions were included in this study. An informed consent to participate in this study was given by all individuals. Characteristics of patients and control groups are summarized in table 1.

Tab. 1: Characteristics of MS patients and normal control groups

<table>
<thead>
<tr>
<th></th>
<th>RRMS*</th>
<th>Normal control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>48</td>
<td>53</td>
</tr>
<tr>
<td>Gender (M : F)</td>
<td>12 : 36</td>
<td>20 : 35</td>
</tr>
<tr>
<td>Age at sampling, years (mean ± SEM)</td>
<td>35.44 ± 4.33</td>
<td>37.55 ± 5.77</td>
</tr>
</tbody>
</table>

RRMS: relapsing-remitting multiple sclerosis

CSF from normal subjects and MS patients were collected by lumbar puncture performed routinely on the basis of the clinical suspicion of neurological disease. None of the patients suffered from known diabetes mellitus, earlier diagnosed tumors of the nervous system or infection. Samples were taken from both male and female patients. For the lumbar puncture the skin were cleaned with 70% alcohol. 0.5 ml of CSF were collected and used for this study. The samples that we used for analysis had no visible sign of contaminating neuroepithelium cells or red blood cells detectable under the microscope. The CSF samples were collected and analyzed for oligoclonal bands (OCBs) by agarose gel electrophoresis on the same day as specimen collection. The finding of OCBs in CSF and not in the serum supports the diagnosis of MS. Only the OCBs positive CSF samples were included in this study for BDNF analysis. The samples subsequently were stored at −70 °C for further analysis.

All data presented are expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using Student’s t-test and only values with $P \leq 0.05$ were considered as significant.

Analysis of CSF protein

Total protein concentration and Western blot: The total concentration of proteins in CSF samples was determined by the Bio-Rad protein assay based on the Bradford dye procedure. For Western blot analysis, CSF samples were mixed with a sample buffer containing 3.2% SDS, 15% glycerol, 2.8 M b-mercaptoeyhanol and 0.0015% bromophenol blue. Samples were applied to a 10% SDS-PAGE gel (Bio-Rad, Milan, Italy) and the proteins obtained were transferred to nitrocellulose sheets, pore size 0.45 lm (Bio-Rad). After incubation for 2 hours at room temperature in the blocking solution (PBS containing 5% skimmed milk), the nitrocellulose sheets were exposed overnight, at 4 °C, to anti-BDNF polyclonal antibody (Abcam) and identified with a peroxidase-labeled mouse IgM PK 4010 Vectastain Avidin Biotin complex kit (Vectorlab, Peterborough, UK). The peroxidase activity was revealed with diaminobenzidine (0.5 mg/ml in PBS with 0.02% hydrogen peroxide). β-Tubulin expression was determined as a protein loading control. After Western blotting, the data were quantified by scanning densitometry.

ELISA: BDNF level in CSF was measured using the sensitive two sited ELISA and antiserum against human BDNF. Microtiter plates (Dynatech, Chantilly, VA) were first coated with 80 ng primary anti-BDNF antibody per well in 0.1 M Tris buffer. After overnight incubation, the plates were blocked with EIA buffer (50mM Tris, pH 7.5, 0.3 M NaCl, 0.1% Triton X-100, 1% BSA and 1% Gelatine). The samples and standards were placed in triplicate wells and incubated overnight at room temperature. After washing a biotinylated secondary antibody (8 ng/ml) was added to each well and the incubation was carried out overnight at room temperature. b-Galactosidase coupled to avidin was then added and after two hours was followed by washing. Finally 200 μM 4-methylumbelliferyl-b-galactoside (Sigma, Poole, UK) in 50mM sodium phosphate and 10mM MgCl2 buffer were added and the amount of fluorescence was measured after 40 minutes incubation at 37 °C using a fluorimeter (Dynatech).
Results

The total concentration of proteins in CSF from patients with MS and control subjects was determined by the Bio-Rad protein assay. The total protein contents of CSF samples from patients with MS and the control subjects were 0.37 ± 0.06 and 0.36 ± 0.04 g/l, respectively. No significant difference has been seen in total protein concentration between two groups (P = 0.55) (Fig. 1).

A Western blot analysis using anti-NGF antibody as a probe confirmed the presence of BDNF (Fig. 2A). In order to obtain semi-quantitative estimates of the relative amounts of 27 kDa protein, an image analyzer was used to determine the intensities of the band in the respective lanes. Quantification of the gels from repeated experiments showed that the amount of BDNF was clearly increased in the CSF from patients with MS when compared with the normal CSF (P < 0.0001) (Fig. 2B).

Using ELISA, it was shown that the level of BDNF in the CSF samples with MS was higher than in normal CSF. The mean BDNF concentration in CSF of MS patients was amounted to 70.54 ± 12.53 pg/ml, which was significantly higher than that of normal, i.e. 8.64 ± 1.52 pg/ml (Fig. 3) (P < 0.0001). This study has shown that BDNF is present in human cerebrospinal fluid. The expression of CSF BDNF in patients with MS is more than that in normal CSF.

Discussion

This study demonstrates that there are increased concentrations of BDNF in the CSF of patients with MS compared with normal subjects. We investigated BDNF as it is an important neurotrophic factor that has the capability to promote neuronal survival and induction of oligodendrocyte proliferation and myelination (17). BDNF belongs to the nerve growth factor (NGF) family of neurotrophins. In the CNS a widespread distribution of BDNF mRNA and protein has been demonstrated with high levels in hippocampal region (5). There are various physiological effects assigned to BDNF such as an important role in the development of fetal and postnatal brain, neurogenesis and synaptic plasticity as well as regeneration of neurons and axons after injury. It is also thought to influence oligodendrocyte proliferation and remyelination (17), which makes it an interesting factor in the context of MS.
BDNF is not only important for the normal development of the peripheral and central nervous systems, but also active in the adult CNS, and might be involved in the pathology and pathophysiology of CNS diseases, notably MS (8). In the brain, BDNF is released by neurons and plays key roles in synaptic plasticity. BDNF and its receptor, TRK, have been found in active MS lesions (25).

Several lines of evidence show that inflammation may have, besides the detrimental effects on the nervous system, a neuroprotective role based on that immune cells are the major source of BDNF in neuroinflammatory diseases (9). Active demyelinating MS plaques harbor numerous BDNF positive inflammatory cells and astrocytes (25). As BDNF is an important cytokine that stimulates oligodendrocyte proliferation and survival, increased CSF BDNF concentration in the patients with MS seen in our study may be a compensatory mechanism in response to loss of oligodendrocyte in MS. In the normal brain, neurons have a major role in the synthesis of BDNF, while in injured brain, glial cells produce BDNF (14). The elevation of BDNF concentration in the CSF of patients with MS in this study may be the result of increased generation of glial cells resulting from brain damage. Since many neurons are destroyed and replaced by reactive gliosis, the elevation of BDNF in CSF may be amplified. If there is extensive damage of neurons, reactive glial cells rather than neurons may be the major source of BDNF in CSF. Production of BDNF by glial cells in patients with MS may represent an active response to neurodegenerative changes. Activated microglia express cytokines and neurotrophic factors that may be neuroprotective (24).

Conclusions

In summary, the CSF BDNF concentration is increased in patients with MS, which suggests that it is involved in neurodegeneration. Thus, we conclude that BDNF is not only a constant component of human CSF, but also might be involved in the pathophysiology of MS.

Acknowledgements

We would like to thank Dr Nouri, for the cerebrospinal fluid samples. The authors would also like to thank Dr E. Mirzajani, Guilian University of Medical Sciences, for ELISA.

References